Commentary on "pANCA Positivity Predicts Lower Clinical Response to Infliximab Therapy among Patients with IBD"
AbstractInflammatory bowel disease (IBD) is a debilitating condition that presents as a spectrum of both gastrointestinal and extraintestinal disorders. The etiology remains unknown, although it is theorized to be immunologically mediated. Despite careful history and physical examination and advances in imaging and endoscopic techniques, differentiating between Crohn disease (CD) and ulcerative colitis (UC) can still be challenging. Many histological diagnoses of indeterminate colitis are eventually reassigned to either CD or UC.1
This content is limited to qualifying members.
If you have an existing account please login now to access this article or view your purchase options.
Create a free account, then purchase this article to download or access it online for 24 hours.
Create a free account, then purchase a subscription to get complete access to all articles for a full year.